Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Aug;34(8):638-644.
doi: 10.1016/j.annonc.2023.05.006. Epub 2023 May 23.

Patient-centered, self-funding dose optimization trials as a route to reduce toxicity, lower cost, and improve access to cancer therapy

I F Tannock  1 , G Bouche  2 , D A Goldstein  3 , Y Goto  4 , A S Lichter  5 , K Prabhash  6 , P Ranganathan  6 , L B Saltz  7 , G S Sonke  8 , G W Strohbehn  9 , R von Moos  10 , M J Ratain  11
Affiliations
Free article
Editorial

Patient-centered, self-funding dose optimization trials as a route to reduce toxicity, lower cost, and improve access to cancer therapy

I F Tannock et al. Ann Oncol. 2023 Aug.
Free article
No abstract available

PubMed Disclaimer

Conflict of interest statement

Disclosure DAG reports personal grants from Merck, Bristol Meyers Squibb and Janssen; consulting fees from VIVIO Health; stock options in VIVIO Health and TailorMed; and employment by Clalit Health Services. YG reports personal grants from AZK and Pfizer; institutional grants from AbbVie, Eli Lilly, Pfizer, Bristol Myers Squibb, Ono, Novartis, Kyorin, Daiichi Sankyo, Novartis, and Preferred Network; honoraria from Eli Lilly, Chugai, Taiho, Boehringer Ingelheim, Ono, Bristol Myers Squibb, Pfizer, MSD, Novartis, Merck, and Thermo Fisher; payment for participation on Advisory Boards or DSMBs from Boehringer Ingelheim, Eli Lilly, Taiho, Pfizer, Novartis, Guardant Health Inc., Illumina, Daiichi Sankyo, Ono Pharmaceutical, Bristol Myers Squibb, and MSD; and has leadership roles in Cancer Net Japan and JAMT. KP reports institutional grants from Alkem Laboratories, Roche, and Pfizer Pvt Ltd. LBS reports consulting fees from Genor Biopharma. GSS reports institutional grants from Agendia, AstraZeneca, Merck, Novartis, Roche, and Seagen; institutional consulting fees from Biovica and Seagen; and has a leadership role in the Dutch Medicines Evaluation Board. GWS reports consulting fees from VIVIO Health and has patents pending for de-escalation methodology and low-dose tocilizumab in viral infections. MJR reports institutional grants from Alliance, Foundation, Bristol-Myers Squibb, AbbVie, Xencor, Incyte, and Boston Biomedical; royalties related to UGT1A1 genotyping from Mayo Medical Laboratories; consulting fees from Apotex, Aptevo, Arvinas Operations, Astellas, Ayala Pharma, bluebird bio, EMD Serono, EQRx, Sandoz, Actavis, Aurobindo, Dr. Reddy’s Laboratories, Mylan, Hetero Labs, Breckenridge Pharmaceutical, Teva, Shilpa, Accord, MSN, Natco, Genentech, Celltrion, Eagle Pharmaceuticals, and Emerson Lake Safety; payments for expert testimony from Apotex, Aurobindo, Accord, MSN, Natco, and Fresenius Kabi; a pending patent for low-dose tocilizumab for COVID-19; payments for advisory boards or DSMBs from Credit Suisse, Mereo, and T3 Pharmaceuticals. RvM reports consultancy fees from Astra Zeneca, Eli Lilly, Gilead Science, GlaxoSmithKline, Merck, MSD, Novartis, Pierre Fabre, PharmaMar, Sanofi, and Vifor; travel grant from Pierre Fabre and Takeda. All other authors have declared no conflicts of interest.

Publication types

LinkOut - more resources